Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Pharmaceuticals
- Disease
- Diagnostic
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6427
License Grant
Licensor entered into a Collaboration Agreement with Licensee to co-develop and commercialize Pimavanserin for neurological and psychiatric indications, including Parkinson’s disease psychosis and Alzheimer’s disease psychosis, in the United States and Canada. Licensor has retained the rights to Pimavanserin in the rest of the world.
License Property
Pimavanserin is a new chemical entity (NCE) currently in Phase III development as a treatment for Parkinson's disease psychosis.
The Licensor announced the completion of enrollment in our first pivotal Phase III clinical trial of pimavanserin in patients with Parkinson's disease psychosis. The Licensor has the option to co-promote pimavanserin in the United States. The Licensee will be responsible for all future costs associated with the development, manufacturing, and commercialization of pimavanserin in all indications with the exception of specified ongoing PDP studies, which will continue to be funded by the Licensor.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 7782
License Grant
The Licensor granted the Licensee certain intellectual property rights in order to expand and strengthen the intellectual property portfolio for the Licensee's serotonin platform, including pimavanserin. In connection with a successful filing of the NDA for NUPLAZID, Licensee would pay milestone payments to the Licensee and if successfully marketed, Royalties.
Field of Use
NUPLAZID™ (pimavanserin) for the treatment of Parkinson’s disease psychosis.
IPSCIO Record ID: 6572
License Grant
Pursuant to an agreement dated February 9, 2009 between the Company, and the Licensor, a California Corporation, the Licensee, is obligated to make payments, from earnings generated from Research derived from the biological specimens from Parkinson's disease patients and control patients provided by the Licensor.
License Property
IP relates to biomarkers for Parkinson's disease.
Field of Use
The Field of Use apply to the healthcare industry. Licensee has an ongoing collaboration with the Parkinson’s Institute to test known Parkinson’s Disease (PD) patients’ blood to identify biomarkers for Parkinson’s Disease from the human plasma proteome microarray marketed as PlasmaScan™. Licensee is also using the H25K Whole Human Genome Microarray to examine PD samples and has identified the world’s first functional mRNA biomarkers for Parkinson’s Disease. An expanded patient study will be used to further validate the PD biomarkers. Licensee is also working with Stanford University to test known Alzheimer’s patients’ blood to identify biomarkers for Alzheimer’s Disease using PlasmaScan and other tools.
IPSCIO Record ID: 26360
License Grant
Upon the effectiveness of the License Agreement, the Licensor will grant to the Licensee an exclusive, worldwide License to develop, make, have made, use, sell, offer to sell, import, and export the Licensed Products.
License Property
The Licensor entered into a License, Development, and Commercialization Agreement with the Licensee to develop and commercialize certain antibodies that target alpha-synuclein, including PRX002, the Licensor's monoclonal antibody for the treatment of Parkinsons disease.
The Licensor will retain certain rights to conduct development of the Licensed Products and an option to co-promote PRX002.
Thereafter, during the term of the License Agreement, the Licensor and the Licensee will work exclusively with each other to research and develop antibody products targeting alpha-synuclein.
A tiered, high single-digit to high double-digit royalties in the teens on ex-U.S. annual net sales, subject to certain adjustments. In the United States, the parties will share all development and commercialization.
Field of Use
After the filing of the investigational new drug application with the U.S. Food and Drug Administration for PRX002 by Licensor, the Licensee will be primarily responsible for developing, obtaining and maintaining regulatory approval for, and commercializing the Licensed Products.
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
